Figure 5

ABZ nanoformulations lead to enhanced antitumor efficacy in the BALB/c nude mice bearing OVCAR3. Treatment started at day 8 after intraperitoneal injection of OVCAR3 tumor cells at day 0. Vehicle, free ABZ, BSA-ABZ 10 nm and Nab-ABZ 200 nm nanoparticle formulations were administered on day 8, 11, 14, 17, 20, 23 by intraperitoneal injection in the mice. To compare the fate of nanoparticles in-vivo, different sizes of particles were administered regardless of particle concentration. A) Tumor weight average B) mice body weight C) mice body circumference (Mean ± SD, n = 4). Compared to free ABZ, no obvious toxicity observed to the mice which were demonstrated well maintained body weight of the mice. Three weeks following treatment BSA-ABZ 10 nm animals group reduced tumor burden very significantly (**p < 0.01) and revealed no evidence of disease, while animals treated with vehicle and free ABZ demonstrated extensive tumor burden. Body weight and abdominal circumference were measured twice weekly.